• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Enliven Therapeutics Inc.

    4/28/25 4:08:39 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELVN alert in real time by email
    DEFA14A 1 d920286ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Enliven Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table below in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


     

    LOGO

     

    P.O. BOX 8016, CARY, NC 27512-9903

     

    LOGO

       LOGO

     

     

     

    Enliven Therapeutics, Inc.

     

    Annual Meeting of Stockholders

     

    Tuesday, June 24, 2025 1:00 p.m., Mountain Time

     

    Annual meeting to be held virtually via the internet - please visit www.proxydocs.com/ELVN for more details.

     

    You must register to attend the meeting online and/or participate at www.proxydocs.com/ELVN

     

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/ELVN

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication is not a form for voting and presents only an overview of the more complete proxy materials, which contain important information and are available to you on the Internet or by mail. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

     

    If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 13, 2025.

             

     

    Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 24, 2025 for stockholders of record as of April 25, 2025

     

    To order paper materials, use one of the following methods.

     

      LOGO

     

    Internet:

    www.investorelections.com/ELVN

     

      LOGO

     

    Call:

    1-866-648-8133

     

      LOGO

     

    Email:

    [email protected]

     

    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

     

             

    LOGO

       
         

    Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

    SEE REVERSE FOR FULL AGENDA      

    Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


     

    LOGO    Enliven Therapeutics, Inc. Annual Meeting of Stockholders

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

    FOR the election of the three Class II directors

    FOR the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for

    fiscal year ending December 31, 2025

     

        

     

    PROPOSAL

     

    1.    To elect the three Class II directors named in the accompanying proxy statement to serve until the 2028 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
       1.01 Rahul D. Ballal, Ph.D.
       1.02 Jake Bauer, M.B.A
       1.03 Andrew Phillips, Ph.D.
    2.    To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for fiscal year ending December 31, 2025.
    3.    To transact other business that may properly come before the Annual Meeting of Stockholders.

    Note: In their discretion, the Named Proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. If no direction is made, this proxy will be voted “FOR” the election of each nominee in Proposal 1 and “FOR” Proposal 2.

    Get the next $ELVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELVN

    DatePrice TargetRatingAnalyst
    12/13/2024$42.00Buy
    BTIG Research
    9/9/2024$37.00Buy
    H.C. Wainwright
    6/11/2024$32.00Outperform
    Robert W. Baird
    4/9/2024$34.00Buy
    Mizuho
    3/29/2023$27.00Buy
    Jefferies
    3/3/2023Outperform
    TD Cowen
    More analyst ratings

    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enliven Therapeutics to Present at Upcoming Investor Conferences

      BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences: TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHAFormat: Fireside ChatDate: Tuesday, May 27, 2025Time: 1:00 p.m. ET Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 4, 2025Time: 4:20 p.m. ET Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, June 10, 2025Time: 4:00 p.m. ET The fireside chats will

      5/22/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

      Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled Enliven to host a webcast and conference call following the oral presentation at EHA on Friday, June 13, at 1:30 p.m. ET Strong balance sheet with $290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027 BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clini

      5/14/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

      Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage bi

      5/14/25 9:56:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Enliven Therapeutics Inc.

      10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)

      5/14/25 4:15:33 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

      5/14/25 4:10:10 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Enliven Therapeutics Inc.

      DEFA14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

      4/28/25 4:08:39 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $81,534 worth of shares (5,000 units at $16.31) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/21/25 6:31:44 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Kintz Samuel sold $82,453 worth of shares (5,000 units at $16.49) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/21/25 6:29:53 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF OPERATING OFFICER Patel Anish sold $122,579 worth of shares (6,667 units at $18.39) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/9/25 6:48:38 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:48:35 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:46:11 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 4:24:01 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Financials

    Live finance-specific insights

    See more
    • Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

      Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled Enliven to host a webcast and conference call following the oral presentation at EHA on Friday, June 13, at 1:30 p.m. ET Strong balance sheet with $290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027 BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clini

      5/14/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

      Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage bi

      5/14/25 9:56:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Enliven Therapeutics with a new price target

      BTIG Research initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $42.00

      12/13/24 7:38:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Enliven Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

      9/9/24 7:29:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Enliven Therapeutics with a new price target

      Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00

      6/11/24 7:13:48 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

      BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e

      4/9/24 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care